{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:29:06Z","timestamp":1770064146654,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.coviro.2017.03.017","type":"journal-article","created":{"date-parts":[[2017,4,15]],"date-time":"2017-04-15T16:47:24Z","timestamp":1492274844000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Direct-acting antivirals: the endgame for hepatitis C?"],"prefix":"10.1016","volume":"24","author":[{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2017.03.017_bib0005","first-page":"153","article-title":"European Association for the Study of the Liver","volume":"66","author":"EASL Recommendations on Treatment of Hepatitis C","year":"2016","journal-title":"J Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_sbref0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0020","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.jhep.2014.08.014","article-title":"Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors","volume":"61","author":"Welzel","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0030","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0040","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_sbref0045","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_sbref0050","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0055","series-title":"European Association for the Study of the Liver Special Conference: New Perspectives in Hepatitis C Virus Infection\u2014The Roadmap for Cure","article-title":"GARNET: high SVR rates following eight-week treatment with Ombitasvir\/Paritaprevir\/Ritonavir+Dasabuvir for patients with HCV genotype 1b infection","author":"Welzel","year":"2016"},{"key":"10.1016\/j.coviro.2017.03.017_bib0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/apt.13883","article-title":"Simeprevir in combination with sofosbuvir in treatment-na\u00efve and experienced patients with hepatitis C virus genotype 4 infection: a phase III, open-label, single-arm study (PLUTO)","volume":"45","author":"Buti","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2017.03.017_bib0070","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0075","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0080","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0085","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I\/II trials","volume":"64","author":"Dore","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0095","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","article-title":"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12 weeks","volume":"64","author":"Feld","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0115","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"PEARL-III study, PEARL-IV study. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2468-1253(16)30001-2","article-title":"A ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial","volume":"1","author":"Asselah","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0125","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"H\u00e9zode","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2017.03.017_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","article-title":"Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection","volume":"152","author":"Kwo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.017_bib0150","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.017_bib0155","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_sbref0160","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0170","unstructured":"FDA Drug Safety Communication, 22 October 2015: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie, http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm468634.htm."},{"key":"10.1016\/j.coviro.2017.03.017_bib0175","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0180","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0185","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/tid.12524","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation","volume":"18","author":"Ciesek","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.017_bib0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","article-title":"Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence\u2014the ANRS CUPILT study","volume":"65","author":"Coilly","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0195","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1097\/01.tp.0000264561.18380.22","article-title":"Treatment of hepatitis C in potential lung transplant candidates","volume":"83","author":"Doucette","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2017.03.017_bib0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.healun.2006.03.011","article-title":"International guidelines for the selection of lung transplant candidates: 2006 update\u2014a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation","volume":"25","author":"Orens","year":"2006","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.coviro.2017.03.017_bib0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2017.03.017_bib0210","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/TP.0000000000000847","article-title":"Novel hepatitis C treatment and the impact on kidney transplantation","volume":"99","author":"Sawinski","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2017.03.017_bib0215","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","author":"Kamar","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.coviro.2017.03.017_bib0220","article-title":"Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients","author":"Eisenberger","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2017.03.017_bib0225","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/liv.13203","article-title":"Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature","volume":"36","author":"D\u2019Ambrosio","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2017.03.017_bib0230","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/liv.13123","article-title":"The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment","volume":"36","author":"De Nicola","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2017.03.017_bib0235","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_sbref0240","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2017.03.017_bib0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0250","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2017.03.017_bib0255","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2017.03.017_bib0260","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0265","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of Ledipasvir\u2013Sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.017_bib0270","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/jvh.12637","article-title":"Effectiveness and safety of Ombitasvir, Paritaprevir, Ritonavir\u00b1Dasabuvir\u00b1Ribavirin: an early access programme for Spanish patients with genotype chronic hepatitis C virus infection","volume":"24","author":"Perrell\u00f2","year":"2017","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.coviro.2017.03.017_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort","author":"Calleja","year":"2017","journal-title":"J Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(17)30048-1","article-title":"Ombitasvir, Paritaprevir, and Ritonavir, with or without Dasabuvir, plus Ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study","author":"Petta","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of Daclatasvir\u2013Sofosbuvir in HCV genotype 1 mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.017_bib0290","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus Sofosbuvir, with or without Ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2017.03.017_bib0295","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus infection with today\u2019s treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.coviro.2017.03.017_sbref0300","article-title":"Impact of treatment on hepatitis C virus transmission and incidence in Egypt: a case for treatment as prevention","author":"Ayoub","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.coviro.2017.03.017_bib0305","series-title":"Monitoring Hepatitis C Treatment Uptake in Australia","author":"The Kirbi Institute","year":"2017"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571630133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571630133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T17:29:47Z","timestamp":1535909387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187962571630133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":61,"alternative-id":["S187962571630133X"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.017","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antivirals: the endgame for hepatitis C?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}